Jaguar health seeking partner to develop and commercialize np300 second-generation antisecretory prescription drug candidate for treatment of general diarrhea in dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no fda-approved drugs to treat general diarrhea in dogs canalevia®-ca1, jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by fda jaguar is attending the december 3-5 pet connect conference and is available for np300 partnership discussions at the event san francisco, ca / accesswire / november 22, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar"), under its jaguar animal health tradename for the veterinary market, today announced that it is seeking a partner to fund and execute the development and commercialization of np300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the u.s. np300 is a novel antisecretory drug with a similar mechanism of action to canalevia®-ca1 (crofelemer delayed-release tablets), the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs. np300 has demonstrated safety in dogs and is sustainably derived from the croton lechleri tree, the same source as that for crofelemer.
JAGX Ratings Summary
JAGX Quant Ranking